Charles River Labs Intl Aktie
161,35 €
Deine Einschätzung
Charles River Labs Intl Aktie
Was spricht für und gegen Charles River Labs Intl in den nächsten Jahren?
Pro
Kontra
Rendite von Charles River Labs Intl im Vergleich
Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
---|---|---|---|---|---|---|---|
Charles River Labs Intl | 2,06 % | 7,15 % | 23,71 % | -13,44 % | -10,55 % | -24,37 % | -20,15 % |
Ironwood Pharmaceuticals | 3,17 % | -5,51 % | -0,83 % | -70,59 % | -71,43 % | -88,23 % | -85,19 % |
Novocure Ltd | 4,91 % | 7,15 % | 12,89 % | -21,54 % | -57,28 % | -82,74 % | -88,85 % |
Iovance Biotherapeutics Inc. | 0,51 % | 6,77 % | 13,19 % | -78,98 % | -71,33 % | -78,23 % | -93,81 % |
Kommentare
News

Charles River Laboratories Schedules Second-Quarter 2025 Earnings Release and Conference Call
Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2025 financial results on Wednesday, August 6th, before the market opens. A conference call has been scheduled

Charles River Announces Endosafe® Cartridge Recycling Program, Strengthening Sustainability Commitment
Charles River Laboratories International, Inc. (NYSE: CRL) today announced a recycling program, developed in partnership with international recycling leader TerraCycle®, to give new life to

Charles River Laboratories to Present at William Blair and Jefferies Conferences
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the William Blair 45th Annual Growth Stock Conference on Tuesday, June 3rd, at 10:00 a.m. CT